Abbreviations: DIM -di-indolylmethane; EGCG -epigallocatechin-3-gallate; EGFepidermal growth factor; EGFR -epidermal growth factor receptor; EMT -epithelial to mesenchymal transition; ER -oestrogen receptor; ESA -epithelial specific antigen; Her2 -EGFR family member ErbB2; I3C -indole-3-carbinol; MS/MS -tandem mass spectrometry; SVM -support vector machine; uPA -urokinase plasminogen activator; VEGF -vascular endothelial growth factor 1 Abstract Accumulating data suggest that dietary phytochemicals have the potential to moderate deregulated signalling or reinstate checkpoint pathways and apoptosis in damaged cells, while having minimal impact on healthy cells. These are ideal characteristics for chemopreventive and combination anti-cancer strategies, warranting substantial research effort into harnessing the biological activities of these agents in disease prevention and treatment. However, this requires further investigation into their mode of action and novel approaches to the development of reliable biomarkers.
Introduction
Epidemiology indicates that the incidence of many common cancers is geographically and environmentally determined and that diets rich in fresh fruit and vegetables confer a lower risk of developing tumours in many target tissues. Around one third of all cancers are thought to be related to unhealthy diet and therefore, in theory, preventable [1] . However, linking particular dietary components to prevention of specific cancers has proved to be a major challenge.
Many phytochemicals of differing chemical structure have anticarcinogenic properties.
They activate cytoprotective enzymes and inhibit DNA damage to block initiation in healthy cells, or modulate cell signalling to eliminate unhealthy cells at later stages in the carcinogenic process. In vitro data for several well-studied compounds indicate that each can affect many aspects of cell biochemistry, but different agents have many similar activities ( Table 1) . Nevertheless effects can be cell-type specific, with transformed cells being particularly sensitive. But despite the exponential increase in knowledge regarding mechanisms of action of these molecules, their success in clinical trials has been limited.
In addition to the difficulties of long-term prevention trials in healthy populations, there are other reasons for this. In cancer therapeutics, emphasis is increasingly placed on targeting tumour subtypes within a particular tissue, but this has not generally been considered for chemopreventive trials. In many instances the crucial in vivo targets for particular dietary molecules are unknown, making it difficult to predict which cancer phenotypes are most likely to be affected. Many phytochemicals are poorly bioavailable and evidence suggests that combinations may be more effective than single agents. There may also be advantages in combining them with chemo-or radio-therapies. Probably the greatest hindrance to more successful trials is the lack of validated biomarkers of efficacy. To enable many more agents to be tested much more quickly, validated surrogate endpoint biomarkers are required, which will accurately determine outcome at a much earlier time in the process of tumour development.
Identifying at risk individuals
In order to optimise the chances of success in cancer chemoprevention trials, the ability to identify those individuals most likely to benefit is clearly important [2] . In the case of primary prevention to inhibit the earliest stages of tumour development, selection has traditionally been based on known environmental and lifestyle risk factors, genetic predisposition and family history. But with such cohorts, obtaining definitive evidence to directly link exposure to a particular dietary agent with prevention of cancer in any target tissue is at best extremely challenging, at worst impossible. In future it is possible that individuals suitable for primary prevention will be identified through screening for more common multiple susceptibility loci, such as those recently reported for breast cancer [3] .
Such loci together could inform on a substantial fraction of the genetic variance in some cancers.
Patients can be recruited at later stages of the carcinogenic process. Secondary prevention is appropriate for those who have already developed premalignant lesions, such as intraepithelial neoplasia or intestinal polyps, the progress of which can be monitored in response to chemopreventive treatments. Several dietary compounds, including indoles and polyphenols have shown promise in this respect, with regression of respiratory papillomatosis, cervical, vulvar and prostate intraepithelial neoplasia and oral leukoplakia [4] [5] [6] [7] . However, the relationship of some of these early lesions to tumour outcome is uncertain. Clearly a strategy involving susceptibility loci would also be relevant at this stage, adding a degree of certainty to the prognosis.
A third strategy is tertiary prevention, which focuses on patients who have been successfully treated for a primary tumour, in order to inhibit development of second primary tumours. Greatest success to date in this respect has resulted from the use of drugs such as tamoxifen and its analogues for breast cancer, and retinoids for skin, head and neck and liver cancer [8] . If phytochemicals have a role at this stage, it is most likely to be as part of a combined therapy.
Arguably a fourth category of patients who could benefit would be those with a superficial or primary tumour, where intervention is designed to prevent invasion and metastases.
While the cellular process of epithelial to mesenchymal transition (EMT) is fundamental to morphogenesis, when reactivated in cancer, it facilitates invasion and metastasis [9] .
Reversing this process could limit metastatic spread, achieving late-stage prevention with enhanced survival. Ability of chemopreventive agents to inhibit EMT or angiogenesis has been demonstrated in a number of animal models. Use of phytochemicals for this purpose would be facilitated by knowledge of the characteristics within the primary tumour which predict invasive potential. We previously showed that the polyphenol, curcumin, modifies the invasive potential of breast cancer cells [10] . Another polyphenol, epigallocatechin-3-gallate (EGCG), was found to inhibit neovascularisation in the chick chorioallantoic membrane assay and when given in drinking water could significantly suppress vascular endothelial growth factor (VEGF)-induced corneal neovascularisation [11] . Such results suggest that EGCG may be a useful inhibitor of angiogenesis in vivo. A number of phytochemicals also affect expression of cadherins, catenins and matrix metalloproteinases (Table 1) , and prognostic metastatic biomarkers for breast cancer, such as urokinase plasminogen activator, uPA/PAI1 and Her2 [12] all of which can modulate invasive capacity.
Tumour subtypes
A key aspect of targeted therapies, which has so far received much less attention in chemoprevention trials, is the concept of tumour subtypes. Tumour development involves the accumulation of multiple mutations which differ from one tumour to the next in the same target tissue. Such changes can be assessed using gene expression profiles to identify patterns of pathway deregulation which inform on disease prognosis and indicate treatment options [13] . 
ER
-negative) and normal breast-like have been identified [15, 16] . Such patterns in cancer cell lines have also been shown to be useful in predicting response to therapeutic agents [13, 17, 18] . However, subtypes identified on the basis of gene expression profiles do not correspond exactly to those identified by immunohistochemistry [19, 20] and used in clinical practice [21] .
Additionally, gene signatures which predict the response to individual agents can be used in combination to predict the efficacy of multidrug regimes [22] . 
Dietary agents in combined treatments
Also of increasing importance is the investigation of combinations of phytochemicals, or their use in conjunction with other therapies, to increase efficacy or decrease unwanted side effects [26, 32] . We have shown in breast cell lines that I3C exhibits enhanced efficacy in combination with src or EGFR kinase inhibitors [24] and in vivo I3C prevented the hepatotoxicity of trabectidin (ET743), an experimental anti-tumour drug with promising activity in sarcoma, breast and ovarian carcinomas, without compromising antitumour efficacy [33] . Curcumin enhances the efficacy of oxaliplatin in both p53 -positive and p53 mutant colon cancer cells [34] . However, caution is required, since it has also been reported to compromise the efficacy of some chemotherapeutic drugs in human breast cancer models [35] .
Proteomics
Methods which do not require a detailed knowledge of mechanisms, initially at least, offer an alternative approach to developing biomarkers and assessing chemopreventive efficacy.
Mass spectrometry of biological samples offers a powerful proteomic tool for the discovery of novel biomarkers and for profiling [36] . Proteins and peptides in clinical samples reflect the intracellular activities of healthy and diseased tissue. Plasma samples subjected to mass spectrometry can provide characteristic protein profiles, when over-and under-expressed peptides are determined by pattern comparison using a variety of machine learning algorithms [37] [38] [39] . This technique should offer the possibility of monitoring plasma profiles in at risk individuals in response to a particular treatment regime.
Development of these methods for cultured cells, would also provide the means to screen effects of chemopreventive agents -for example, to estimate the lowest concentration of agent that causes a change in profile; to look for dose-response in altered peaks; to compare effects of one agent in different cell types; to compare the signatures between compounds in the same cell type; and to enable identification of signature peaks.
Individual proteins can be identified by correlating the sequences of tryptic peptides generated by tandem mass spectrometry (MS/MS) with sequences in protein databases.
The evolutionary algorithms with support vector machine (SVM) supervised learning enable identification of biomarkers with the highest diagnostic and prognostic potential.
The effectiveness of combined treatments could also be explored. Nuclear fractions could provide enrichment for investigating changes in transcription factors and cell cycle-related proteins. In view of the importance of protein phosphorylation in proliferation, differentiation and apoptosis, development of techniques selective for phosphopeptides would provide added value [40, 41] .
Conclusions
In order to fully appreciate the potential for dietary compounds in cancer prevention and bridge the gap between apparent in vitro efficacy and clinical use, a number of approaches are required. Attention must be paid to the use of physiologically relevant concentrations, to chronic exposure and to 3D cultures, to more accurately mimic in vivo situations.
Validation of potential mechanisms in appropriate animal models is also important. The mechanistic biomarkers identified in vitro need to be verified in human tissues as being central to the carcinogenic process. Finally genomics and proteomics approaches offer novel ways of predicting clinical efficacy. 
